Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 4: Clinical Pharmacy Services
4CPS-203
COMPARISON OF PIRFENIDONE VERSUS NINTENDANIB IN IDIOPATHIC PULMONARY FIBROSIS
4CPS-202
OPTIMISATION OF SUBCUTANEOUS BIOLOGICAL THERAPIES IN RHEUMATIC AND DERMATOLOGICAL DISEASES
4CPS-200
EFFECTIVENESS OF ERENUMAB AND GALCANEZUMAB IN THE PREVENTION OF MIGRAINE
4CPS-198
THE IMPACT OF A PHARMACIST-LED MEDICATION REVIEW ON THE MEDICINE RISK SCORE: A NONRANDOMISED CONTROLLED STUDY
4CPS-197
Evaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs
4CPS-195
Medication-related readmissions: documentation and communication to the next healthcare providers and patients
ACPS-189
ASSOCIATION BETWEEN THE DEVELOPMENT OF IMMUNE-RELATED ADVERSE EVENTS AND THE EFFECTIVENESS OF IPILIMUMAB IN ADVANCED MELANOMA
4CPS-183
Prevention of coronavirus contamination from the environment using an air-cleaning closed system drug-transfer device
4CPS-176
ORAL IVERMECTIN EFFECTIVENESS IN THE TREATMENT OF PERMETHRIN-RESISTANT SCABIES: A DESCRIPTIVE AND RETROSPECTIVE OBSERVATIONAL STUDY
4CPS-175
MEDICATION REGIMEN COMPLEXITY INDEX AMONG SOLID ORGAN TRANSPLANT PATIENTS
4CPS-164
DURABILITY OF ORAL DUAL ANTIRETROVIRAL THERAPY IN HIV PATIENTS
4CPS-157
IMPACT OF COVID-19 PANDEMIC ON PATIENTS TREATED WITH BIOLOGICAL DRUGS AND ENZYME REPLACEMENT THERAPIES
4CPS-155
APPROPRIATENESS OF PHARMACOTHERAPY IN NURSING HOMES: PHARMACY AND GERIATRICS SERVICES COORDINATION PROJECT
4CPS-150
Ability to assess acute kidney injury in patients admitted to hospital
4CPS-148
Use of remdesivir in severe Sars-CoV-2 pneumonia in critically and non-critically ill patients
Pages
« first
‹ previous
…
41
42
43
44
45
46
47
48
49
…
next ›
last »
Follow Us